Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.
about
Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosisMOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancerCountering immunotoxin immunogenicity.Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis.Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition.Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.
P2860
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@ast
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@en
type
label
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@ast
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@en
prefLabel
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@ast
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@en
P2093
P2860
P356
P1476
Phase I trial of EpCAM-targeti ...... combination with cyclosporin.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2015.380
P407
P577
2015-11-10T00:00:00Z